Hoth Therapeutics Inc. (HOTH) delivered promising interim data on Thursday from its CLEER-001 trial, which is testing HT-001 in cancer patients receiving EGFR inhibitor therapy. The results from the open-label pharmacokinetic cohort were about as clean as early-stage trial data gets.

The Trial Results

Here's what stands out: 100% of evaluable patients hit clinical response by Week 6. That's not a typo—every single evaluable patient improved. Disease severity, measured using the ARIGA scale, dropped by approximately 50% from baseline. All evaluable patients reached an ARIGA score of 1 or less by Week 6, putting the entire cohort in the low-severity disease range.

The improvements weren't just statistically significant—they showed up early and stuck around. Patients started improving as early as Week 3, and those gains held through Week 6, suggesting both rapid onset and durability of response.

Beyond the primary endpoint, supportive clinical measures told a consistent story. Oncology toxicity (measured by CTCAE) improved by roughly 34%, and patient-reported pruritus—medical speak for itching, a common side effect of EGFR inhibitors—dropped by about 37%. That's meaningful because EGFR therapy can cause miserable skin reactions, and anything that makes treatment more tolerable is a win for patients.

Earlier Preclinical Work

This isn't Hoth's only pipeline play. Back in September 2025, the company shared preclinical findings on HT-KIT, a precision antisense candidate targeting KIT-driven cancers. In preclinical models of gastrointestinal stromal tumors (GIST) and systemic mastocytosis, HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, with statistically significant tumor shrinkage by day 8.

Stock Performance and Technical Picture

Despite the clinical progress, HOTH stock is trading in bearish territory in the near term. Shares are currently 2.7% below the 20-day simple moving average and 3.5% below the 50-day SMA. Over the past 12 months, the stock has declined approximately 22.79% and sits closer to its 52-week low of $0.6554 than its high of $2.115.

The RSI sits at 45.29, which is neutral—neither overbought nor oversold. Meanwhile, MACD is above its signal line, indicating bullish momentum in the short term. The combination suggests mixed momentum for the stock.

Key resistance sits at $1.05, with support at $1.00.

On Thursday, Hoth traded with session volume of 2.199 million shares compared to an average volume of 397.07 thousand.

Analyst View

Analysts remain optimistic despite the stock's recent struggles. HOTH carries a Buy rating with an average price target of $6.50. D. Boral Capital maintained a Buy rating with a $5.00 target on December 4, 2025.

At last check on Thursday, Hoth Therapeutics stock was up 2.86% at $1.075.